ĀÜĄņĀŅĀ×

Victor is Senior Vice President, Drug Discovery at Hexagon Bio. He obtained a B.S. degree in Chemistry from the University of Utah in 1997 and a Ph.D. degree in Organic Chemistry from Harvard University in 2003. He joined the Medicinal Chemistry department at Amgen in 2003 and contributed to numerous small molecule drug discovery programs including Tie-2 kinase, Aurora kinase (AMG 900), S1P1 (AMG 369), PI3Kļ” (AMG 511), Pim kinase, and RORļ§T. He led the KRASG12C research team from project inception to the identification and characterization of AMG 510, which went on to become Amgenā€™s first in class KRASG12C inhibitor LUMAKRASā„¢ (sotorasib), approved in the United States in 2021 for the treatment of KRASG12C-positive non-small cell lung cancer. In 2020 he joined Oncovalent Therapeutics as Vice President, Chemistry, where he directed drug discovery efforts and platform technology focused on identifying and advancing covalent inhibitors for oncology indications.